Skip navigation
Skip navigation

A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates

Johnston, Tom; Millar, Zak A; Huot, Philippe; Wagg, Keith; Theile, Sherri; Salomonczyk, Danielle; Yong-Kee, Christopher J; Gandy, Michael N; McIldowie, Matthew; Lewis, Katie; Gomez-Ramirez, Jordie; Lee, Joohyung; Fox, Susan H; Martin-Iverson, Mathew; Nash, Joanne E; Piggott, Matthew J; Brotchie, Jonathan M


Treatment of Parkinson's disease with dopaminergic agents, such as L-DOPA, is frequently compromised by disabling side effects, particularly dyskinesia and a shortening in duration of antiparkinsonian action. Studies in animal models and anecdotal evidence from a patient with Parkinson's disease show that the illicit drug ecstasy (MDMA) can alleviate these side effects, though with many drawbacks (e.g., psychoactivity). MDMA itself thus has little therapeutic potential. On the basis of known...[Show more]

CollectionsANU Research Publications
Date published: 2012
Type: Journal article
Source: FASEB Journal
DOI: 10.1096/fj.11-195016


File Description SizeFormat Image
01_Johnston_A_novel_MDMA_analogue,_2012.pdf565.83 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator